EpCAM is expressed by a broad spectrum of epithelial solid cancer types in the range of > 90% (as e.g. ovarian-, gastric-, colonic-, pancreas-, bladder-, prostate-, endometrial- and non- small cell lung cancer) [24, 25] and Catumaxomab is able to bind even at a very low EpCAM expression levels due to its high affinity and cell binding potential [20] making Catuvab applicable for a broad spectrum of solid cancer surgeries. Here, EPCAM is linked to non-small cell lung carcinoma.